my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
24-09-2010: OncoMethylome Sciences announced that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.
OncoMethylome's biomarker is stable, highly accurate, and, unlike many other biomarkers, allows for the analysis of non-invasive tissue samples.
"We are very pleased to enter into this agreement with GSK. This project was initiated in 2007 and is a prime example of how we can bring our considerable regional strengths to bear on global healthcare issues," said Jan Groen, Ph.D., Chief Executive Officer of OncoMethylome. "Furthermore, this agreement marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK, and underpins our strategy of leveraging our methylation specific PCR platform in the rapidly emerging field of companion diagnostics and personalized medicine."
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
OncoMethylome Sciences Changes its Name to MDxHealth
OncoMethylome Sciences SA announced that its Extraordinary General Shareholders' Meeting passed the resolution on the proposed name change of the company to MDxHealth SA. The name change was unanimously supported by the shareholders present or represented at the meeting. As announced in t ... more
OncoMethylome Sciences Reinforces U.S. Presence with Key Executive Appointments
OncoMethylome Sciences SA announced the appointments of Dr. Melissa A. Thompson as Vice President Regulatory Affairs and Quality Assurance, and of Mr. Christopher (Chris) Thibodeau as Vice President Commercial Operations. Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said: "Wit ... more
OncoMethylome Sciences announced that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed. OncoMet ... more
OncoMethylome Sciences is a bio-tech company dedicated to developing tests for early cancer detection and personalized treatment decisions. Specifically, OncoMethylome Sciences develops DNA gene methylation tests to assist physicians (i) in detecting cancer at an early stage with a high le ... more
OncoMethylome Sciences is a bio-tech company dedicated to developing tests for early cancer detection and personalized treatment decisions. Specifically, OncoMethylome Sciences develops DNA gene methylation tests to assist physicians (i) in detecting cancer at an early stage with a high le ... more
OncoMethylome Sciences is a bio-tech company dedicated to developing tests for early cancer detection and personalized treatment decisions. Specifically, OncoMethylome Sciences develops DNA gene methylation tests to assist physicians (i) in detecting cancer at an early stage with a high le ... more
Priaxon enters collaboration with GSK on Protein-Protein-Interactions
Priaxon announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modul ... more
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055 ... more
KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
